http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005500981-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 2001-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2005500981-A |
| titleOfInvention | CCR5 antagonist and DP-178 polypeptide for treating viral infections |
| abstract | The present invention relates to a novel combination therapy for treating HIV comprising a CCR5 antagonist or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of DP-178 polypeptide or a pharmaceutically acceptable derivative thereof. I will provide a. The combination of the present invention is more tolerable by reducing the administration frequency of DP-178 polypeptide from subcutaneous administration twice a day to once a day or 2-3 times a week A simple treatment schedule. The present invention provides a method for treating HIV infection in an individual in need of treatment for HIV infection, the method comprising a therapeutically effective amount of a CCR5 antagonist or a pharmaceutically acceptable salt thereof and a therapeutically effective amount. Administering in combination with an amount of DP-178 polypeptide or a pharmaceutically acceptable derivative thereof. |
| priorityDate | 2000-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 325.